sr 33557 has been researched along with quetiapine in 1 studies
Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (quetiapine) | Trials (quetiapine) | Recent Studies (post-2010) (quetiapine) |
---|---|---|---|---|---|
50 | 3 | 1 | 56 | 0 | 28 |
Protein | Taxonomy | sr 33557 (IC50) | quetiapine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 3.3008 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 3.3447 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.5787 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 3.0007 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.4914 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 2.615 | |
D(2) dopamine receptor | Homo sapiens (human) | 1.3299 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.1003 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.4208 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.4264 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.4293 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0966 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.1178 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 3.3008 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.4264 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0396 | |
D(3) dopamine receptor | Homo sapiens (human) | 1.1632 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.2135 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.33 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 5.7772 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.2935 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
1 other study(ies) available for sr 33557 and quetiapine
Article | Year |
---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |